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Enhanced triage for patients with suspected cardiac chest 
pain: the History and Electrocardiogram-only Manchester 
Acute Coronary Syndromes decision aid
Abdulrhman Alghamdia,e, Laura Howardb, Charles Reynardc, Philip Mossd, 
Heather Jarmand, Kevin Mackway-Jonesb,c, Simon Carleyb,c  
and Richard Bodya,b,c    
Objectives Several decision aids can ‘rule in’ and ‘rule 
out’ acute coronary syndromes (ACS) in the Emergency 
Department (ED) but all require measurement of blood 
biomarkers. A decision aid that does not require biomarker 
measurement could enhance risk stratification at triage 
and could be used in the prehospital environment. We 
aimed to derive and validate the History and ECG-only 
Manchester ACS (HE-MACS) decision aid using only the 
history, physical examination and ECG.
Methods We undertook secondary analyses in three 
prospective diagnostic accuracy studies that included 
patients presenting to the ED with suspected cardiac 
chest pain. Clinicians recorded clinical features at the time 
of arrival using a bespoke form. Patients underwent serial 
troponin sampling and 30-day follow-up for the primary 
outcome of ACS. The model was derived by logistic 
regression in one cohort and validated in two similar 
prospective studies.
Results The HE-MACS model was derived in 796 
patients and validated in cohorts of 474 and 659 patients. 
HE-MACS incorporated age, sex, systolic blood pressure 
plus five historical variables to stratify patients into four 
risk groups. On validation, 5.5 and 12.1% (pooled total 
9.4%) patients were identified as ‘very low risk’ (potential 
immediate rule out) with a pooled sensitivity of 99.5% 
(95% confidence interval: 97.1–100.0%).
Conclusion Using only the patient’s history and ECG, 
HE-MACS could ‘rule out’ ACS in 9.4% of patients while 
effectively risk stratifying remaining patients. This is a 
very promising tool for triage in both the prehospital 
environment and ED. Its impact should be prospectively 
evaluated in those settings. European Journal of 
Emergency Medicine 26: 356–361 Copyright © 2018 The 
Author(s). Published by Wolters Kluwer Health, Inc.
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Background
Recent advances in biomarker technology have ena-
bled earlier reassurance for patients who present to the 
Emergency Department (ED) with symptoms that are 
compatible with an acute coronary syndrome (ACS). 
There is now convincing evidence that serial cardiac 
troponin testing can help clinicians to rule out ACS over 
as little as 2 h with a contemporary assay [1,2] and 1 h 
with a high sensitivity assay [3]. It may even now be 
possible to ‘rule out’ acute myocardial infarction (AMI) 
with a single blood test, obviating the need for serial 
sampling [4,5].
The Manchester Acute Coronary Syndromes (MACS) 
and Troponin-only MACS (T-MACS) decision aids are 
validated tools that can both ‘rule in’ ACS, ‘rule out’ ACS 
and risk stratify remaining patients after a single blood 
test in the ED [6,7]. Both MACS and T-MACS calculate 
the probability that a patient has ACS and use that prob-
ability to stratify patients into one of four risk groups. 
The key difference between these models is that MACS 
incorporates two biomarkers (cardiac troponin and heart-
type fatty acid binding protein), whereas T-MACS incor-
porates only cardiac troponin. However, both rely on 
biomarker measurement.
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In the prehospital environment and when patients arrive 
in the ED for triage, the ability to test biomarker concen-
trations is not usually available. A decision aid that can 
‘rule in’, ‘rule out’ and accurately risk stratify patients 
with suspected ACS without requiring biomarker meas-
urement would have substantial advantages in these set-
tings. Our primary objective was to derive and externally 
validate a decision aid, called ‘history and electrocardio-
gram MACS’ (HE-MACS), to achieve this.
Methods
Design and setting
We undertook this work in three stages: a derivation study 
followed by two external validation studies. We elected 
not to pool data from the two validation studies because 
of the potential for important heterogeneity between the 
studies. The derivation study took place at Manchester 
Royal Infirmary (an inner city university-affiliated hos-
pital with a regional cardiology service); validation study 
took place at Stepping Hill Hospital, Stockport (a sub-
urban community hospital) and validation study was the 
Bedside Evaluation of Sensitive Troponin study. This is a 
multicentre study incorporating an extensive programme 
of research. For this analysis, we included patients from 
Manchester Royal Infirmary and St George’s NHS Trust, 
London, UK. Each of the three studies is a prospective 
diagnostic accuracy study. All analyses presented here are 
secondary analyses.
Participants
In each study, we included adult patients presenting to 
the ED with suspected cardiac chest pain. We excluded 
patients with another medical condition necessitat-
ing hospital admission and those whose symptoms had 
occurred over 24 h (derivation study and validation study 
1) or 12 h (validation study 2) prior to arrival. In valida-
tion study 2 we excluded patients who were diagnosed 
with ST-elevation myocardial infarction in the ED. Full 
details of the methodology for the derivation study and 
validation study 1 have previously been reported [6,7]. 
All patients provided written informed consent and the 
studies were approved by the National Research Ethics 
Service.
Data collection and processing
Clinical data were recorded by the treating clinician in 
the ED using a bespoke case report form (Supplementary 
Appendix, Supplemental digital content 1, http://links.
lww.com/EJEM/A229). ECGs were also interpreted by the 
treating clinician. All patients underwent serial cardiac 
troponin testing. In the derivation study and validation 
study 1, samples were drawn on arrival in the ED and 
12 h after symptom onset. In validation study 2, samples 
were drawn on arrival and 3 h later. The troponin assays in 
use were cardiac troponin T (99th percentile 0.01 ng/ml, 
10% coefficient of variation at 0.03 ng/ml, Roche Elecsys 
4th generation; Roche Diagnostics, GmBH, Penzberg, 
Germany) in the derivation study and high sensitivity 
cardiac troponin T (99th percentile 14 ng/l, 10% coef-
ficient of variation at 12 ng/l, Roche Elecsys 5th gener-
ation, Roche Diagnostics) in both validation studies. 
Patients were followed up after 30 days by telephone and 
chart review. If patients were persistently uncontactable 
we contacted their general practitioner.
Outcomes
The primary outcome for this analysis was a diagnosis of 
ACS. Patients were considered to have ACS if they had 
AMI or a major adverse cardiac event (MACE) within 30 
days. The diagnosis of AMI was adjudicated by two inde-
pendent investigators with disagreements being resolved 
by discussion. AMI was defined in accordance with the 
universal definition of myocardial infarction, requiring a 
rise and/or fall of cardiac troponin with at least one concen-
tration above the 99th percentile of the assay in conjunc-
tion with symptoms or signs compatible with myocardial 
ischaemia, ECG changes, imaging evidence of new loss 
of viable myocardium or angiographic identification of 
intracoronary thrombus [8]. MACE was defined as death 
(all cause), AMI or coronary revascularization (coronary 
artery bypass grafting or percutaneous coronary interven-
tion) occurring within 30 days of presentation.
Statistical analysis
We derived HE-MACS by forward stepwise logistic 
regression. On the basis of previous work in the deriva-
tion study [6,9], variables that had been found to predict 
(P < 0.05) the diagnosis of ACS on univariate analysis and 
that had good interobserver reliability (κ > 0.6) were con-
sidered for inclusion in the model [6]. We explored the 
relationship between age and the incidence of MACE by 
stratifying age into deciles and cross-tabulating this with 
the incidence of MACE. Having noted an approximately 
linear relationship, we considered age as a continuous 
variable in the model. Similarly, we explored the relation-
ship between systolic blood pressure and the incidence 
of MACE. In this instance, we noted a markedly higher 
incidence of MACE in the bottom decile, which related 
to a cutoff set at ~100 mmHg. We, therefore, considered 
systolic blood pressure as a dichotomous variable with a 
cutoff set at 100 mmHg. Calibration plots were created 
by stratifying the calculated probability of ACS (using 
HE-MACS) into deciles. The incidence of MACE was 
then plotted against the mean probability in each decile. 
The intercept and slope were calculated by linear regres-
sion using GraphPad Prism, version 5.04 (GraphPad Inc., 
La Jolla, California, USA).
Having derived the HE-MACS model, we then stratified 
patients into four risk groups, based on the decisions that 
are likely to be available to clinicians who would apply 
HE-MACS in practice: ‘very low risk’ (possible immedi-
ate ‘rule out’), ‘low risk’ (potentially suitable for care in 
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an ambulatory environment), ‘moderate risk’ (potentially 
suitable for care in the ED environment) and ‘high risk’ 
(potentially ‘rule in’ ACS). The thresholds for assigning 
patients to the different risk groups were set by receiver 
operating characteristic (ROC) analysis. First, we cal-
ibrated the model to achieve 100% sensitivity for ‘very 
low risk’ versus all other categories. While 100% is not the 
minimum acceptable sensitivity, we aimed for optimum 
sensitivity in the derivation phase in the knowledge that 
sensitivity is likely to be lower on validation. For ‘low 
risk’ versus all other groups, we calibrated the model to 
achieve 90% sensitivity (roughly equivalent to a normal 
initial high sensitivity cardiac troponin T concentration 
[10]). Finally, we aimed to achieve a specificity of 95% for 
the high-risk group.
To evaluate diagnostic performance in each individual 
study, we calculated test characteristics with 95% confi-
dence intervals (CIs) and calculated the area under the 
ROC curve using the nonparametric method. We then 
calculated pooled sensitivity, specificity and likelihood 
ratios using the DerSimonian Laird (random effects) 
model. We used a χ2-test to test for statistical heteroge-
neity between studies. The proportions of patients iden-
tified as being at ‘very low risk’ in each validation study 
were aggregated to yield the pooled proportion.
Statistical analyses were undertaken using SPSS, ver-
sion 23.0 (SPSS Inc., Chicago, Illinois, USA) except 
for (a) calculation of test characteristics, for which we 
used MedCalc, version 13.1.2.0 (MedCalc Software, 
Mariakerke, Belgium); and (b) and diagnostic meta-anal-
ysis, for which we used Meta-Disc [11]. To calculate the 
lower bound of the 95% CI when the negative predictive 
value (NPV) was 100% we used the epi.stats package in 
R, version 3.5.0 (University of Auckland, Auckland, New 
Zealand). As this work is a secondary analysis, we did 
not undertake a sample size calculation specific to the 
derivation and validation of HE-MACS. However, the 
derivation cohort had been powered to derive a decision 
rule with 15 predictors, assuming a 20% prevalence of 
ACS with 5% loss to follow-up, requiring a total of 790 
participants.
Results
We included 796 patients in the derivation study. A total 
of 153 (19.2%) patients had prevalent AMI. After 30 days, 
a total of 118 (14.8%) patients had undergone coronary 
revascularization, seven (0.9%) had died (all of which 
had an adjudicated initial diagnosis of AMI) and two 
(0.3%) had incident AMI. Thus, a total of 179 (22.5%) 
patients had ACS (either prevalent AMI or at least one 
incident MACE within 30 days). In validation study 1, 
we included 474 patients of which 80 (16.9%) had AMI 
and 93 (19.6%) had ACS. In validation study 2, there were 
659 participants including 74 (11.2%) with AMI and 91 
(13.8%) with ACS. Follow-up was complete to 30 days in 
each study. A participant flow diagram is shown in Fig. 1. 
Fig. 1
Participant flow diagram for the derivation and validation studies. AMI, acute myocardial infarction.
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Baseline characteristics of participants in each study are 
shown in Table 1.
The HE-MACS model we derived incorporated eight 
variables, as shown in Table 2. This model had an area 
under the ROC curve of 0.82 (95% CI: 0.78–0.86). We 
used the ROC analysis to stratify patients into four risk 
groups, as detailed in the Supplementary Appendix 
(Supplemental digital content 1, http://links.lww.com/
EJEM/A229). The model was well calibrated with a slope 
of 0.99 and intercept 0.0027. A calibration plot is avail-
able in the Supplementary Appendix (Supplemental 
digital content 1, http://links.lww.com/EJEM/A229). The 
proportion of patients assigned to each risk group and 
the number of AMI and ACS in each group are shown 
in Table 3.
The test characteristics of the model in the validation 
studies are shown in Table 4, together with pooled esti-
mates of sensitivity and specificity. The areas under the 
ROC curves in the validation studies were 0.78 (95% 
CI: 0.73–0.83) and 0.73 (95% CI: 0.67–0.78) respec-
tively. Calibration plots are shown in the Supplementary 
Appendix (Supplemental digital content 1, http://
links.lww.com/EJEM/A229). There was no evidence 
of between-study heterogeneity for the sensitivity of 
HE-MACS (P = 0.24, I2: 27.6%), but there was evidence 
of heterogeneity for specificity (P < 0.001, I2: 92.2%). In 
the validation studies, the total proportion ‘ruled out’ 
would have been 5.5% in validation study 1 and 12.1% 
in validation study 2) with one missed ACS. The one 
patient missed had an adjudicated diagnosis of AMI. This 
30-year-old male presented with a typical chest pain and 
had high-sensitive cardiac troponin T concentrations of 
198 and 316 ng/l. Although that patient was assigned an 
adjudicated diagnosis of AMI, subsequent cardiac mag-
netic resonance imaging was consistent with a diagnosis 
of myocarditis, which was the final diagnosis assigned by 
the patient’s clinical team.
Discussion
We have successfully derived and externally validated a 
decision aid that could ‘rule out’ ACS in 9.4% of patients 
using only the history and ECG with high NPV. The 
HE-MACS can also be used to effectively risk strat-
ify the remaining patients. To our knowledge, there are 
currently no similar validated tools that can achieve this 
without biomarker testing, which requires the availability 
of laboratory equipment. This special and unique feature, 
therefore, opens up a number of important opportunities 
to apply HE-MACS more widely than the original MACS 
and T-MACS models.
First, HE-MACS could be used at triage when patients 
first arrive in the ED. Achieving rapid ‘rule-out’ for 
patients soon after arrival, without biomarker evaluation, 
could help to alleviate the growing pressures faced by 
crowded EDs, and accurately assign patients triage cate-
gory (i.e. time to be seen by a clinician).
Second, the algorithm could be used in the prehospital 
environment. To date, the requirement to measure bio-
marker concentrations has been an important barrier to 
the implementation of rapid ‘rule-out’ strategies in this 
field. One potential solution would be to implement 
a point of care biomarker testing. However, the ability 
to ‘rule out’ ACS without any biomarker measurement 
would be cheaper, easier to implement and would facil-
itate more rapid decisions. Finally, the algorithm could 
be used in settings where blood testing is not available, 
such as in primary care. This is often the first medical 
contact for patients with chest pain and a high percent-
age of those patients are referred to the ED [12]. Thus, 
HE-MACS could help to avoid unnecessary ED referrals 
and immediately rule out ACS in those settings.
To our knowledge, there are no comparable triage 
tools for use in patients with suspected ACS that do 
not involve the use of biomarkers and that have used 
Table 1 Baseline characteristics of included patients
 Derivation study 
(n = 796) [n (%)]
Validation study 1 
(n = 474) [n (%)]
Validation study 2 
(n = 659) [n (%)]
Age [mean (SD)] 
(years)
58.9 (14.2) 63.6 (15.7) 56.2 (15.2)
Men 481 (60.4) 277 (58.4) 402 (61.0)
Previous myocardial 
infarction
195 (24.5) 141 (29.7) 168 (25.5)
Previous angina 258 (32.4) 188 (39.7) 178 (27.0)
Hypertension 399 (50.1) 199 (42.0) 178 (27.0)
Hyperlipidaemia 379 (47.6) 191 (40.3) 253 (38.4)
Diabetes mellitus 141 (17.7) 80 (16.9) 132 (20.1)
Current smoking 247 (31.0) 100 (21.1) 145 (22.0)
Acute ECG ischaemia 227 (28.5) 108 (22.8) 56 (8.5)
Time from symptom 
onset <3 h
303 (38.1) 218 (46.2) 376 (56.8)
Table 2  Derivation of the HE-MACS model by logistic regression
Variables β Coefficient Odds ratio (95% CI)
Sweating observed (a) 1.426 4.2 (2.4–7.3)
Acute ECG ischaemia (b)a 1.838 6.3 (4.2–9.5)
Pain radiating to the right arm or 
shoulder (c)
0.734 2.1 (1.2–3.7)
Vomiting associated with pain (d) 0.996 2.7 (1.4–5.3)
Systolic blood pressure <100 mmHg 
(e)
1.353 3.9 (1.4–10.3)
Current tobacco smoker (f) 0.675 2.0 (1.3–3.1)
Age (g) 0.024 1.03 (1.01–1.04)b
Male sex (h) 0.462 1.6 (1.0–2.5)
Constant −4.416 NA
ACS, acute coronary syndrome; CI, confidence interval; HE-MACS, History and 
Electrocardiogram-only Manchester Acute Coronary Syndromes.
The probability of ACS can be calculated from this model as follows: probabil-
ity = 1/1 + e−(1.426a+1.838b+0.734c+0.996d+1.353e+0.675f+0.024g+0.462h−4.416). For dichoto-
mous variables, a value of ‘1’ is assigned if the characteristic is present and ‘0’ 
if absent.
aThe ECGs were interpreted by the treating clinician. We deliberately left this 
variable a little subjective, thus allowing clinicians to have some freedom in their 
interpretation of the ECG. Acute ischaemia included ST-deviation and abnormal T 
inversion, but those with fixed changes that were not known to be old could have 
been coded as having no ‘acute ischaemia’.
bOdds ratio for a 1-year increase in age.
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adjudicated outcomes with contemporary reference 
standards. A systematic review from 2016 found no 
similar triage tools from the era of cardiac troponin 
testing that have been validated in the emergency set-
ting [13]. Another systematic review, from 2013, which 
focused on clinical prediction models for use in the 
prehospital setting, identified five relevant studies but 
none have been validated to ‘rule out’ ACS without 
biomarker testing and based on contemporary refer-
ence standards [14].
The volume of previous work in this field highlights the 
clinical demand for a validated tool that could be used 
to rapidly ‘rule out’ ACS without biomarker testing. It 
also demonstrates the importance of our current findings. 
We have derived and externally validated a decision aid 
that could be rapidly applied either in the prehospital 
environment or upon patient arrival in the ED. Its use 
could obviate the need for further investigation in 9.4% 
of patients. While this may appear to be a modest pro-
portion of the overall total, it is worth noting that chest 
pain is one of the most common reasons for emergency 
ambulance calls and the most common reason for emer-
gency hospital admission. The overall impact of reducing 
unnecessary transport to the hospital or facilitating rapid 
discharge from ED triage for these patients is therefore 
likely to be substantial.
It is now possible to measure cardiac biomarkers using 
portable devices with a turnaround time of 10–15 min. If 
such a technology is successfully validated in the prehos-
pital environment, for example, alongside a validated risk 
score [15], and if the effectiveness of such technology 
is greater than the HE-MACS algorithm derived here, 
then the algorithm presented here may have limited 
applicability. However, the advantage of the algorithm 
presented here is that it does not require any biomarker 
testing with its associated costs, and could therefore be 
used even when such technology is not available.
Limitations
It is important to acknowledge that the HE-MACS model 
has been derived and validated in secondary analyses of 
prospectively collected data. All of the clinical data, for 
example, ECG interpretation, were recorded based on 
the interpretation of emergency physicians. Also, having 
HE-MACS derived and validated from different popu-
lations result in different rule out proportions. In addi-
tion, having a wide confidence interval in the validation 
study 2 (91.8–99.8) for the NPV could indicate that one 
of 10 patients could be missed. Before clinical imple-
mentation, therefore, we must evaluate HE-MACS in 
the settings in which it is likely to have the most impact, 
including the prehospital field and ED triage or other. To 
do this, we must, therefore, determine the feasibility of 
applying the model when used by paramedics and ED 
triage nurses, and determine whether diagnostic accuracy 
is maintained.
We did not include pain severity as a potential predictor 
in this work, as these data were not collected during the 
derivation study. However, previous work from validation 
study 1 has shown that pain severity is poorly predictive 
of AMI [16].
Conclusion
We have derived and validated the HE-MACS clinical 
decision aid that could be used to rapidly risk stratify 
patients with suspected cardiac chest pain without requir-
ing biomarker evaluation. Importantly, this model could 
allow ACS to be rapidly ‘ruled out’ in 9.4% of patients 
Table 3  Proportion of patients with ACS and prevalent AMI in the four risk groups for the HE-MACS decision aid in each cohort
 Very low risk [n (%)] Low risk [n (%)] Moderate risk [n (%)] High risk [n (%)]
Derivation
 Total number of patients 44 (5.5) 187 (23.5) 455 (57.2) 110 (13.8)
 Patients with ACS 0 (0.0) 14 (7.5) 86 (18.9) 79 (71.8)
 Patients with AMI 0 (0.0) 9 (4.8) 69 (15.2) 75 (68.2)
Validation study 1
 Total number of patients 26 (5.5) 93 (19.6) 311 (65.6) 44 (9.3)
 Patients with ACS 0 (0.0) 3 (3.2) 67 (21.5) 23 (52.3)
 Patients with AMI 0 (0.0) 2 (2.2) 56 (18.0) 22 (50.0)
Validation study 2
 Total number of patients 80 (12.1) 183 (27.8) 376 (57.1) 20 (3.0)
 Patients with ACS 1 (1.3) 14 (7.7) 64 (17.0) 12 (60.0)
 Patients with AMI 1 (1.3) 11 (6.0) 51 (13.6) 11 (55.0)
ACS, acute coronary syndrome; AMI, acute myocardial infarction; CI, confidence interval; HE-MACS, History and Electrocardiogram-only Manchester Acute Coronary 
Syndromes.
Table 4  Test characteristics of HE-MACS as a ‘rule out’ tool in the 
validation studies
 Validation study 1 Validation study 2
n, % ‘ruled out’ 26, 5.5 (3.6–8.0) 80, 12.1 (9.6–15.1)
Sensitivity 100.0 (96.1–100.0) 98.9 (94.0–100.0)
Specificity 6.8 (4.5–9.8) 13.9 (11.2–17.0)
PPV 20.9 (20.3–21.2) 15.5 (15.0–16.1)
NPV 100.0 (86.8–100) 98.8 (91.8–99.8)
LR+ 1.07 (1.04–1.10) 1.15 (1.10–1.20)
LR− 0.00 (NA) 0.08 (0.01–0.56)
The test characteristics of the model in the validation studies (i.e. ‘very low risk’ 
versus all other risk groups; 95% confidence intervals in parentheses). Figures are 
for the primary outcome of ACS.
ACS, acute coronary syndrome; HE-MACS, History and Electrocardiogram-only 
Manchester Acute Coronary Syndromes; LR+, positive likelihood ratio; LR−, neg-
ative likelihood ration; NPV, negative predictive value; PPV, positive predictive 
value.
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with high sensitivity and NPV. We must now validate the 
model when applied by paramedics in the prehospital 
setting and by nurses at triage in the ED.
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